EGFR and cancer: Notably, over half of the druggable proteins were found to be targets for multiple drugs, with EGFR for example being targeted by 56 phase 1–4 drugs, of which 20 are approved therapeutics for the treatment of various cancer types (Supplementary Fig. S12, Supplementary Fig. S13, Supplementary Data 3).